Literature DB >> 2686409

Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. A double-blind crossover study.

S Chodosh1, J Tuck, K D Stottmeier, D Pizzuto.   

Abstract

Two separate acute bacterial exacerbations of chronic bronchitis and/or asthma were treated in 22 patients in a double-blind crossover study. One course of treatment consisted of 750 mg of ciprofloxacin twice daily and the other of 500 mg of ampicillin four times a day; each drug was given for 14 days. Patients were observed initially, every three to four days during therapy, and weekly during the post-therapy period. Observations that were recorded included graded chest symptoms and physical findings, vital signs, hematologic parameters, and objective sputum measurements (daily volume, purulence, differential quantitative cytology, bacterial counts, and physical properties). Both antibiotic regimens were effective in resolving these acute bacterial exacerbations. Paired t test analysis revealed that ciprofloxacin is as clinically effective as ampicillin in the treatment of acute bacterial exacerbations in chronic bronchial disease, and appears to be superior in clearing bacterial pathogens from the sputum.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2686409     DOI: 10.1016/0002-9343(89)90035-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  4 in total

1.  Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year.

Authors:  G Torrance; V Walker; R Grossman; J Mukherjee; D Vaughan; J La Forge; N Lampron
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

2.  Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.

Authors:  S Chodosh; S Lakshminarayan; H Swarz; S Breisch
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

Review 3.  Role of quinolones in the treatment of bronchopulmonary infections, particularly pneumococcal and community-acquired pneumonia.

Authors:  J P Thys; F Jacobs; B Byl
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

4.  Rufloxacin once daily in acute exacerbations of chronic bronchitis.

Authors:  M Dirksen; J Focht; J Boerema
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.